33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence
    Meeting Abstract

    Bajorin, D. F.; Sharma, P.; Sims, R. B.; Sandler, A.; Lerner, S. P.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)
    Meeting Abstract

    Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • To determine the predictive value of preoperative breast MRI in selecting patients appropriate for nipple-sparing mastectomy
    Meeting Abstract

    Barry, J. M.; de Alcantara Filho, P.; D'Arcy, C.; Stempel, M.; Sacchini, V.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER)
    Meeting Abstract

    Basch, E. M.; Abernethy, A. P.; Mullins, C. D.; Tiglao, M. R.; Tunis, S. R.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Balar, A. V.; Milowsky, M. I.; Apolo, A. B.; Ostrovnaya, I.; Iasonos, A.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I. R.; Gallagher, D. J.; Bajorin, D. F.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC)
    Meeting Abstract

    Ang, K. K.; Zhang, Q. E.; Rosenthal, D. I.; Nguyen-Tan, P.; Sherman, E. J.; Weber, R. S.; Galvin, J. M.; Schwartz, D. L.; El-Naggar, A. K.; Gillison, M. L.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial
    Meeting Abstract

    Antonarakis, E. S.; Heath, E. I.; Smith, D. C.; Rathkopf, D. E.; Blackford, A. L.; Danila, D. C.; King, S.; Frost, A.; Carducci, M. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
    Meeting Abstract

    Armstrong, G. T.; Chen, Y.; Kawashima, T.; Sklar, C. A.; Mulrooney, D. A.; Chow, E. J.; Border, W.; Durand, J.; Mertens, A.; Stovall, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Clinical/pathologic features and survival of patients with fibrolamellar-hepatocellular carcinoma (FLL-HCC): Data from the Fibrolamellar-Hepatocellular (FLL-HCC) Consortium
    Meeting Abstract

    Ang, C.; Venook, A. P.; Choti, M. A.; DeMatteo, R. P.; Kelley, R. K.; Cosgrove, D.; McGuire, J. P.; Torbenson, M. S.; Pawlik, T. M.; Jarnagin, W. R.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Prognostic impact of post-prostatectomy PSA slope determined with a novel nucleic acid detection immunoassay (NADIA ProsVue) for total PSA
    Meeting Abstract

    Moul, J. W.; Semmes, O. J.; Vessella, R.; McDermed, J. E.; Lilja, H.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save